CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Cash Flows From Operating Activities:
Net (Loss)	$ (4,742,023)	$ (4,824,210)
Adjustments To Reconcile Net Loss To Net Cash Used In Operating Activities:
Depreciation and Amortization	130,215	200,089
Share Based Compensation - Non-employee	19,071
Share Based Compensation- Employees	2,259,316	2,679,468
Loss on Disposal of Assets	3,350	506
Changes in Assets and Liabilities:
(Increase) Decrease in Accounts Receivable	(344,500)	(1,176,787)
(Increase) in Inventory	(2,291,108)	(1,292,152)
(Increase) in Other Assets	160,406	(42,733)
Increase (Decrease) in Accounts Payable	(1,914,780)	425,252
Increase (Decrease) in Other Liabilities	2,160,268	(507,795)
Increase (decrease) Deferred License Revenue	(498,120)	(481,686)
Increase (decrease) in deferred drug license revenue	(93,181)	3,954,546
Changes in Assets and Liabilities	(2,821,015)	878,645
Cash (Used In) Operating Activities	(5,151,086)	(1,065,502)
Cash Flows From Investing Activities:
Purchase of Investments Available for Sale	31,123
Purchase of Equipment	(162,003)	(202,430)
Proceeds from Sale of Assets	450
Cash Provided by (Used In) Investing Activities	(130,430)	(202,430)
Cash Flows From Financing Activities:
Proceeds from the Issuance of Common Shares and Purchase Warrants		77,250
Cash Provided By Financing Activities		77,250
Effects of exchange rate changes	632
(Decrease) Increase In Cash	(5,280,884)	(1,190,682)
Cash At Beginning Of Period	17,180,594	31,198,182
Cash At End Of Period	$ 11,899,710	30,007,500
Supplemental Cash Flow Information:
Interest Paid		$ 404,527